Heterogeneous benefit of early sacubitril/valsartan initiation after PCI in elderly patients with left ventricular dysfunction: myocardial recovery and mid-term cardiovascular outcomes - Takeaways - MDSpire

Heterogeneous benefit of early sacubitril/valsartan initiation after PCI in elderly patients with left ventricular dysfunction: myocardial recovery and mid-term cardiovascular outcomes

  • By

  • Jian Li

  • Chunxia Tang

  • May 29, 2026

  • 0 min

Share

  • 1

    The study evaluated the timing of sacubitril/valsartan initiation after PCI in elderly patients with left ventricular dysfunction.

  • 2

    Patients were classified into three groups: early initiation (≤7 days), delayed initiation (14–28 days), and no sacubitril/valsartan.

  • 3

    Early initiation was associated with the greatest improvement in left ventricular ejection fraction and reductions in cardiac injury biomarkers.

  • 4

    During 12-month follow-up, major adverse cardiovascular events occurred in 8.3% of the early group, compared to 20.8% and 25.0% in the delayed and control groups.

  • 5

    The findings suggest that early initiation of sacubitril/valsartan may lead to better myocardial recovery and lower cardiovascular risk in this population.

Original Source(s)

Heterogeneous benefit of early sacubitril/valsartan initiation after PCI in elderly patients with left ventricular dysfunction: myocardial recovery and mid-term cardiovascular outcomes

  • by Jian Li, Chunxia Tang

  • May 29, 2026

Related Content

Analysis of factors associated with cognitive impairment in elderly patients hospitalized with chronic heart failure

Outcomes following coronary artery bypass grafting with temporary left ventricular assist device support

Serum uric acid levels and cardiorenal complication prevalence in hypertensive patients before and after the COVID-19 pandemic: a retrospective cross-sectional study from a tertiary traditional Chinese medicine hospital